Experimental antibody combo shows promise against tough cancers

NCT ID NCT05307874

Terminated Disease control Sponsor: ImCheck Therapeutics, an Ipsen company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help control the disease, but more research is needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICT01 (an antibody) combined with low-dose interleukin-2 (IL-2) and optionally pembrolizumab
What this could lead to: If it works, this could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 56 participants, so results may not apply to everyone. Side effects are possible, and the combination may not shrink tumors in most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma colorectal cancer metastatic melanoma metastatic prostate carcinoma ovarian cancer pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

IUCT Oncopole Claudius Regaud

Toulouse, France
Institute Gustave Roussy

Paris, France
The Institute of Cancer Research

Sutton, United Kingdom
University Carl Gustav Carus

Dresden, Germany
Universitätsklinikum Wuerzburg

Würzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.